Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The entire integration and transition of the brands is expected to be completed by March 2022
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
The 50-bed hospital is positioned to address complexities specific to women and children, going beyond a birthing facility
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Subscribe To Our Newsletter & Stay Updated
